SEC For	rm 4																			
	FORM	4 U	NITED	STA	ΓES	SE			ES A		<b>EXCHAI</b> 20549	NGE	COM	MISSIO	N	OME			<u> </u>	
Check	this box if no I		OF CHANGES IN BENEFICIAL OWNERSHIP										OMB APPROVAL OMB Number: 3235-0287							
to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed							pursuant to Section 16(a) of the Securities Exchange Act of 1934											Estimated average burden hours per response: 0.5		
1 Nome e					or S	Sectio	on 30(h)	of the	e Invest	ment (	Company Act o	of 1940		Relationshi	of Ren	ortina Pe	erson(s)	to Issu	ier	
1. Name and Address of Reporting Person <sup>*</sup> Samsara BioCapital GP, LLC															5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 10/16/2023									Officer (give title Other (specify below) below)					
628 MIDDLEFIELD ROAD					4. lf	4. If Amendment, Date of Original Filed (Month/Day/Year) 6									r Joint/G	Foup Fili	ng (Cheo	k App	licable	
(Street) PALO ALTO CA 94301					Form file X Form file Person										One Re More th					
(City) (State) (Zip)				Rι	Rule 10b5-1(c) Transaction Indication															
						Cheo satis	ck this b fy the af	ox to ir firmativ	ndicate th ve defen	nat a tr se con	ansaction was n ditions of Rule 1	nade pur .0b5-1(c)	suant to a . See Instr	contract, instr uction 10.	uction or	written pl	an that is	intende	ed to	
		Table	I - Non-	Deriva	ative	Sec	curitie	es Ao	cquire	ed, D	isposed o	f, or B	enefici	ially Own	ed					
1. Title of Security (Instr. 3) Date (Month/Day/Yee				(ear)	Exec if any	eemed ution Date, / th/Day/Year)		3. Transaction Code (Instr. 8)			cquired (A) or D) (Instr. 3, 4 and		5. Amount of Securities Beneficially Owned Follow		Form: (D) or	Indirect	Indire Benef	. Nature of ndirect Beneficial Dwnership		
								,	Code	v	Amount	(A) or (D)	Price	Reported Transacti (Instr. 3 a	on(s)		,	(Instr.		
Common Stock 10/16/202						:3								1				By		
					23						2,189,781	A	\$6.85	6,788,609		I		Samsara BioCapital, L.P. <sup>(1)</sup>		
		Ta									sposed of, , convertib				d					
1. Title of Derivative	2. Conversion	3. Transaction	3A. Deem	ed	4. Trans		5.1	lumbe	er 6. Da	ate Ex	ercisable and	7. Title	e and	8. Price of	9. Num derivat		10. Owners		11. Nature	
Security (Instr. 3)	or Exercise Price of Derivative Security	Date (Month/Day/Year)	if any		Code 8)				s I			Amount of Securities Underlying Derivative Security (Instr 3 and 4)		Derivative Security (Instr. 5) r.	Securit Benefic Owned Follow Report	ties cially ing ed ction(s)	y Direct ( or Indir (I) (Inst		D) Beneficia D) Ownersh ect (Instr. 4)	
							and	15)	_				Amount or	-						
					Code	v	(A)	(D)	Date Exe	e rcisabl	Expiration Date	Title	or Number of Shares							
		f Reporting Person <sup>*</sup> Dital <u>GP, LLC</u>																		
<u>Sdilisd</u>		<u>Jildi GP, LLC</u>				_														
(Last) (First) (Middle) 628 MIDDLEFIELD ROAD																				
(Street)						-														
PALO A	LTO	CA	9430	1																
(City)		(State)	(Zip)																	
		f Reporting Person <sup>*</sup> pital, L.P.																		
(Last) 628 MII	DLEFIEL	(First) D ROAD	(Middl	e)																
(Street) PALO A	LTO	CA	9430	1		-														

## Explanation of Responses:

(State)

(Zip)

1. Shares are held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its respective pecuniary interest therein. Dr. Akkaraju is a director of Issuer and files separate Section 16 reports.

(City)

Samsara BioCapital GP, LLC,<br/>By /s/ Srinivas Akkaraju,10/18/2023Managing MemberSamsara BioCapital, L.P., By:<br/>Samsara BioCapital GP, LLC,<br/>its General Partner, By /s/10/18/2023Srinivas Akkaraju, Managing<br/>Member10/18/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.